Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : Workshop recommendations

Korbet, 1999, Clinical picture and outcome of primary focal segmental glomerulosclerosis, Nephrol Dial Transplant, 14, S68, 10.1093/ndt/14.suppl_3.68 Orloff, 2005, Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population, Physiol Genomics, 21, 212, 10.1152/physiolgenomics.00201.2004 Shalhoub, 1974, Pathogenesis of lipoid nephrosis —a disorder of T-cell function, Lancet, 2, 556, 10.1016/S0140-6736(74)91880-7 Meyrier, 2005, Mechanisms of disease: focal segmental glomerulosclerosis, Nat Clin Practice Nephrol, 1, 44, 10.1038/ncpneph0025 Iseki, 2003, Proteinuria and the risk of developing end-stage renal disease, Kidney Int, 63, 1468, 10.1046/j.1523-1755.2003.00868.x El Nahas, 2005, Chronic kidney disease: the global challenge, Lancet, 365, 331, 10.1016/S0140-6736(05)17789-7 Kriz, 2005, Pathways to nephron loss starting from glomerular diseases—insights from animal models, Kidney Int, 67, 404, 10.1111/j.1523-1755.2005.67097.x Ruggenenti, 1998, Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. ‘Gruppo Italiano di Studi Epidemiologici in Nefrologia’ (GISEN), Kidney Int, 53, 1209, 10.1046/j.1523-1755.1998.00874.x Vincent, 2003, Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials, Ann Surg, 237, 319, 10.1097/01.SLA.0000055547.93484.87 Bellomo, 1993, Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?, Nephron, 63, 249, 10.1159/000187205 Hoyer, 1986, Thromboembolic complications in children with nephrotic syndrome. Risk and incidence, Acta Paediatr Scand, 75, 804, 10.1111/j.1651-2227.1986.tb10294.x Ordonez, 1993, The increased risk of coronary heart disease associated with nephrotic syndrome, Kidney Int, 44, 638, 10.1038/ki.1993.292 Eddy, 2003, Nephrotic syndrome in childhood, Lancet, 362, 629, 10.1016/S0140-6736(03)14184-0 Brodehl, 1982, The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Päd iatrische nephrologie (APN), Klin Padiatr, 194, 162, 10.1055/s-2008-1033800 Arbeitsgemeinschaft für Pädiatrische Nephrologie, 1988, Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children, Lancet, 1, 380 Bargman, 1999, Management of minimal lesion glomerulonephritis—– evidence-based recommendations, Kidney Int, 55, S3, 10.1046/j.1523-1755.1999.07002.x Cattran, 2001, Idiopathic membranous glomerulonephritis, Kidney Int, 59, 1983, 10.1046/j.1523-1755.2001.0590051983.x Troyanov, 2004, Toronto Glomerulonephritis Registry Group: Idiopathic membranous nephropathy: definition and relevance of a partial remission, Kidney Int, 66, 1199, 10.1111/j.1523-1755.2004.00873.x Troyanov, 2005, Focal and segmental glomerulosclerosis: definition and relevance of a partial remission, J Am Soc Nephrol, 16, 1061, 10.1681/ASN.2004070593 Tejani, 1995, Current concepts of pathogenesis of nephrotic syndrome, Vol 7, 1 Zietse, 1992, Effects of cyclosporin on glomerular barrier function in nephrotic syndrome, Clin Sci, 82, 641, 10.1042/cs0820641 Meyrier, 1994, Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome, Kidney Int, 45, 1446, 10.1038/ki.1994.189 Ambalavanan, 1996, Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy, J Am Soc, 7, 290 Heering, 2001, Influence of cyclosporine A on renal function in patients with glomerulonephritis. Deutsche Med, Wochenschrift, 126, 1093, 10.1055/s-2001-17603 Kokui, 1992, Cyclosporin reduces proteinuria in rats with aminonucleoside nephrosis, J Pathol, 166, 297, 10.1002/path.1711660313 Schrijver, 1995, Cyclosporin A reduces albuminuria in experimental anti-GBM nephritis indendently from changes in GFR, Nephrol Dial Transplant, 10, 1149, 10.1093/ndt/10.7.1149 Desassis, 1997, Antiproteinuric effect of cyclosporin A in adriamycin nephropathy in rats, Nephron, 75, 336, 10.1159/000189558 Chen, 2003, Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model, J Am Soc Nephrol, 14, 690, 10.1097/01.ASN.0000046964.15831.16 Serkova, 2003, Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides, Curr Opin Investig Drugs, 4, 1287 Midtvedt, 2003, C2 monitoring in maintenance renal transplant recipients: is it worthwhile?, Transplantation, 76, 1236, 10.1097/01.TP.0000085046.39523.D5 Kusaba, 2005, More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome, Pharmacotherapy, 25, 52, 10.1592/phco.25.1.52.55617 Mihatsch, 1990, A consensus report: cyclosporin A therapy for psoriasis, Br J Dermatol, 122, 1 Feutren, 1992, Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of cyclosporin in autoimmune diseases, N Engl J Med, 326, 1654, 10.1056/NEJM199206183262502 Lowe, 1997, Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure, J Am Acad Dermatol, 37, 671, 10.1016/S0190-9622(97)70205-6 Fujinaga, 2006, Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome, Arch Dis Child, 91, 666, 10.1136/adc.2005.080960 Kandaswamy, 2007, Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression, Transplantation, 83, 722, 10.1097/01.tp.0000256179.14038.e2 Kim, 2006, Urinary transforming growth factor-beta-induced gene-h3 (betaig-h3) as a sensitive predictor in chronic cyclosporine nephrotoxicity, Transplant Proc, 38, 1314, 10.1016/j.transproceed.2006.02.070 Betton, 2005, Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid, Cancer Biomark, 1, 59, 10.3233/CBM-2005-1107 Tanaka, 2004, Single-dose daily administration of cyclosporine A for relapsing nephrotic syndrome, Pediatr Nephrol, 19, 1055, 10.1007/s00467-004-1508-y Ogahara, 2005, Advantage of preprandial cyclosporine (CyA) administration for absorption profile in nephrotic syndrome, J Am Soc Nephrol, 16, 779A Lowenstein, 1981, Renal failure in minimal change nephrotic syndrome, Am J Med, 70, 227, 10.1016/0002-9343(81)90754-3 Koomans, 2001, Pathophysiology of acute renal failure in idiopathic nephrotic syndrome, Nephrol Dial Transplant, 16, 221, 10.1093/ndt/16.2.221 Ehrich, 1993, Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie, Eur J Pediatr, 152, 357, 10.1007/BF01956754 Nolasco, 1986, Adult-onset nephrotic syndrome: a long-term follow-up, Kidney Int, 29, 1215, 10.1038/ki.1986.130 Korbet, 1988, Minimal-change glomerulopathy of adulthood, Am J Nephrol, 8, 291, 10.1159/000167603 Oemar, 1991, Eight and 12 week courses of cyclophosphamide in nephrotic syndrome, Arch Dis Child, 66, 751, 10.1136/adc.66.6.751 Meyrier, 2005, Minimal change and focal-segmental glomerulosclerosis, vol 1., 439 Yoshioka, 2000, A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome, Kidney Int, 58, 317, 10.1046/j.1523-1755.2000.00168.x British Association for Paediatric Nephrology, 1991, Levimasole for corticosteroid-dependent nephrotic syndrome in childhood, Lancet, 337, 1555, 10.1016/0140-6736(91)93257-A Hogg, 2006, Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study group, Clin J Am Soc Nephrol, 1, 1173, 10.2215/CJN.00550206 Choi, 2002, Mycophenolate mofetil treatment for primary glomerular disease, Kidney Int, 61, 1098, 10.1046/j.1523-1755.2002.00214.x Carruthers, 1993, Report of the Canadian hypertension society consenus conference. I. introduction, Can Med Assoc J, 149, 289 Hoyer, 1986, Cyclosporin in frequently relapsing minimal change nephrotic syndrome, Lancet, 2, 335, 10.1016/S0140-6736(86)90017-6 Hoyer, 2006, Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective randomized trial, J Am Soc Nephrol, 17, 1151, 10.1681/ASN.2005090922 Tejani, 1991, A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children, Nephron, 59, 96, 10.1159/000186526 Niaudet, 1992, Comparison of cyclosporine and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial, Pediatr Nephrol, 6, 1, 10.1007/BF00856817 Ponticelli, 1993, Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial, Nephrol Dial Transplant, 8, 1326 Meyrier, 1991, Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology, Clin Nephrol, 35, S37 Meyrier, 1997, Treatment of idiopathic nephrotic syndrome with cyclosporine A, J Nephrol, 10, 14 El-Husseini, 2005, Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience, Nephrol Dial Transplant, 20, 2433, 10.1093/ndt/gfi059 Hulton, 1994, Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood, Pediatr Nephrol, 8, 401, 10.1007/BF00856511 Matsumoto, 2001, Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults, Clin Nephrol, 55, 143 Singh, 1999, One centre experience with cyclosporine in refractory nephrotic syndrome in children, Pediatr Nephrol, 13, 26, 10.1007/s004670050557 Ponticelli, 1999, The place of cyclosporine in the management of primary nephrotic syndrome, Biodrugs, 12, 327, 10.2165/00063030-199912050-00002 Iijima, 2002, Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome, Kidney Int, 61, 1801, 10.1046/j.1523-1755.2002.00303.x Niaudet, 1994, Cyclosporine in the treatment of idiopathic nephrosis, J Am Soc Nephrol, 4, 1049, 10.1681/ASN.V541049 Niaudet, 1995, Serial renal biopsies in children with idiopathic nephrosis receiving cyclosporine, Contrib Nephrol, 114, 78, 10.1159/000424287 Durkan, 2006, Non-corticosteroid treatment for nephrotic syndrome in children Bar Oz, 2001, Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis, Transplantation, 71, 1051, 10.1097/00007890-200104270-00006 Ruf, 2004, Prevalence of WT1 mutation in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome, Kidney Int, 66, 564, 10.1111/j.1523-1755.2004.00775.x Boute, 2000, NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome, Nat Genet, 24, 349, 10.1038/74166 Kim, 2003, CD-2 associated protein haploinsufficiency is linked to glomerular disease susceptibility, Science, 300, 1298, 10.1126/science.1081068 Kaplan, 2000, Mutations in ACTN4, encoding a-actinin-4, cause familial focal segmental glomerulosclerosis, Nat Med, 24, 251, 10.1038/73456 Winn, 2005, A mutation in the TRCP6 cation channel causes familial focal segmental glomerulosclerosis, Science, 308, 1801, 10.1126/science.1106215 Walz, 2005, Slit or pore? A mutation of the ion channel TRPC6 causes FSGS, Nephrol Dial Transplant, 20, 1777, 10.1093/ndt/gfh961 Ruf, 2004, Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome, J Am Soc Nephrol, 15, 722, 10.1097/01.ASN.0000113552.59155.72 Korbet, 2003, Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis, Semin Nephrol, 23, 219, 10.1053/snep.2003.50020 Korbet, 2002, Treatment of primary focal segmental glomerulosclerosis, Kidney Int, 62, 2301, 10.1046/j.1523-1755.2002.00674.x Matalon, 2000, Treatment of focal segmental glomerulosclerosis, Semin Nephrol, 20, 309 Ponticelli, 1999, Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?, Am J Kidney Dis, 34, 618, 10.1016/S0272-6386(99)70384-7 Habashy, 2003, Interventions for steroid-resistant nephrotic syndrome: a systematic review, Pediatr Nephrol, 18, 906, 10.1007/s00467-003-1207-0 Cattran, 1999, A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis, Kidney Int, 56, 2220, 10.1046/j.1523-1755.1999.00778.x Ponticelli, 1993, A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome, Kidney Int, 43, 1377, 10.1038/ki.1993.194 Heering, 2004, Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis, Am J Kidney Dis, 43, 10, 10.1053/j.ajkd.2003.09.027 Alexopoulos, 2000, Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis, Nephrol Dial Transplant, 15, 1348, 10.1093/ndt/15.9.1348 Lieberman, 1996, A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children, J Am Soc Nephrol, 7, 56, 10.1681/ASN.V7156 Ingulli, 1992, Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome, J Am Soc Nephrol, 3, 254, 10.1681/ASN.V32254 Mitsoni, 2002, Second hour measurement of cyclosporine (C2) in children with nephrotic syndrome, Pediatr Nephrol, 17, c97 Laluck, 1999, Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy, Am J Kidney Dis, 33, 1026, 10.1016/S0272-6386(99)70138-1 Hogan, 1995, A review of therapeutic studies of idiopathic membranous glomerulopathy, Am J Kidney Dis, 25, 862, 10.1016/0272-6386(95)90568-5 Shiiki, 2004, Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan, Kidney Int, 65, 1400, 10.1111/j.1523-1755.2004.00518.x Ponticelli, 1992, Remissions and relapses in idiopathic membranous nephropathy, Nephrol Dial Transplant, 7, 85 Ponticelli, 1995, A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy, Kidney Int, 48, 1600, 10.1038/ki.1995.453 Ponticelli, 1998, A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy, J Am Soc Nephrol, 9, 444, 10.1681/ASN.V93444 Wetzels, 2007, Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide, A J Kidney Dis, 50, 248, 10.1053/j.ajkd.2007.05.015 Cattran, 2001, Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial, Kidney Int, 59, 1484, 10.1046/j.1523-1755.2001.0590041484.x Alexopoulos, 2006, Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome, Nephrol Dial Transplant, 21, 3127, 10.1093/ndt/gfl360 Cattran, 1995, A controlled trial of cyclosporine in patients with progressive membranous nephropathy, Kidney Int, 47, 1130, 10.1038/ki.1995.161 Rostoker, 1993, Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy, Nephron, 63, 335, 10.1159/000187219 Fritsche, 1999, Treatment of membranous glomerulonephropathy with cyclosporin A: how much patience is required?, Nephrol Dial Transplant, 14, 1036, 10.1093/ndt/14.4.1036 Iida, 2000, Effect of cyclosporine therapy on idiopathic membranous nephropathy presented with refractory nephrotic syndrome, Clin Exp Nephrol, 4, 81, 10.1007/s101570050068 Lee, 2006, Idiopathic membranous nephropathy in children, Pediatr Nephrol, 21, 1707, 10.1007/s00467-006-0246-8 Alexopoulos, 2002, Efficacy of cyslosporin in difficult-to-treat idiopathic membranous nephropathy, Nephrology, 7, 51, 10.1046/j.1440-1797.2002.00087.x